Press Release

View printer-friendly version << Back

Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments on Tuesday, March 10th

The company will host a conference call at 8:30am ET

BOSTON--(BUSINESS WIRE)--Feb. 25, 2020-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report fourth quarter and full year 2019 financial results before the Nasdaq Global Market open on Tuesday, March 10, 2020. Jill C. Milne, Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss fourth quarter and last year’s financial results.

Conference Call Dial-In Information:

Participant Toll-Free Dial-In Number:

(877) 388-2733

Participant International Dial-In Number:

(541) 797-2984

Pass Code:

3621269

Please specify to the operator that you would like to join the “Catabasis Fourth Quarter and Full Year 2019 Results Call.”

Interested parties may access a live audio webcast of the conference via the investor section of the Catabasis website, www.catabasis.com. Please connect to the Catabasis website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. The webcast will be archived for 90 days.

About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com.

Andrea Matthews
Catabasis Pharmaceuticals, Inc.
T: (617) 349-1971
amatthews@catabasis.com

Source: Catabasis Pharmaceuticals, Inc.

Andrea Matthews
Catabasis Pharmaceuticals, Inc.
T: (617) 349-1971
amatthews@catabasis.com